NVO
Novo Nordisk
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.
Market Cap: 429 Billion
Primary Exchange: NEW YORK STOCK EXCHANGE INC.
Website: https://www.novonordisk.com/
Shares Outstanding: 3.44 Billion
Float: 0
Dividend: 1.0256367081804478 (0.01%)
Beta: 0.5730284977523475
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1739 trading days
From: 2015-08-03 To: 2020-01-14
Lowest Point:
Value Hunting: ADRs Earning Top Quality Scores
via: SeekingAlpha at 2019-06-12 05:33:18:000
Source: CNN. Background As the Warren Buffett Indicator keeps flirting with the all-time high (see below), long-term value/quality-focused investors in the U.S. may want to reduce their home-country bias a bit by looking overseas in order to expand the investable universe. Source: G… read more...
Value Hunting: ADRs Earning Top Quality Scores
via: SeekingAlpha at 2019-06-12 05:33:18:000
Source: CNN. Background As the Warren Buffett Indicator keeps flirting with the all-time high (see below), long-term value/quality-focused investors in the U.S. may want to reduce their home-country bias a bit by looking overseas in order to expand the investable universe. Source: G… read more...
Late-stage study confirms safety profile of Novo's oral semaglutide
via: SeekingAlpha at 2019-06-11 10:57:15:000
Novo Nordisk ( NVO +0.5% ) announces positive results from the Phase 3 PIONEER 6 study evaluating the effect of oral semaglutide on cardiovascular (CV) risk. The data were presented at the American Diabetes Association Scientific Sessions in San Francisco. More news on: Novo Nordisk … read more...
Lilly's Trulicity reduced CV risk in large-scale T2D study
via: SeekingAlpha at 2019-06-10 05:17:16:000
Results from the large-scale Phase 3 REWIND study evaluating the effects of Eli Lilly's (NYSE: LLY ) once-weekly Trulicity (dulaglutide) on reducing cardiovascular (CV) risk in people with type 2 diabetes (T2D) showed a sustained benefit regardless of the presence of established CV dise… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|---|---|---|---|---|---|---|---|
| 2019-08-16 | 2019-08-19 | 2019-08-20 | 2019-08-09 | 3.0 | Interim | |||
| 2019-03-22 | 2019-04-02 | 2019-03-25 | 2019-03-21 | 5.15 | Interim | |||
| 2018-08-17 | 2018-08-21 | 2018-08-20 | 2018-08-08 | 3.0 | Interim | |||
| 2018-03-23 | 2018-04-03 | 2018-03-26 | 2018-03-22 | 4.85 | Interim | |||
| 2017-08-18 | 2017-08-22 | 2017-08-21 | 2017-08-10 | 3.0 | Interim | |||
| 2017-03-23 | 2017-04-04 | 2017-03-27 | 2017-03-24 | 4.6 | Interim | |||
| 2016-08-12 | 2016-08-16 | 2016-08-15 | 2016-08-08 | 3.0 | Interim | |||
| 2015-03-19 | 2015-03-31 | 2015-03-23 | 2015-03-20 | 5.0 | Increase | |||
| 2020-03-27 | 2020-04-07 | 2020-03-30 | 0.7873899 | Cash | ||||
| 2020-08-14 | 2020-08-25 | 2020-08-17 | 2020-08-06 | 0.5175159 | Cash | |||
| 2021-03-26 | 2021-04-07 | 2021-03-29 | 0.949358 | Cash | ||||
| 2021-08-16 | 2021-08-25 | 2021-08-17 | 0.557094 | Cash | ||||
| 2022-03-25 | 2022-04-05 | 2022-03-28 | 2022-03-02 | 1.03603 | Cash | |||
| 2022-08-12 | 2022-08-23 | 2022-08-15 | 0.0 | |||||
| 2022-08-12 | 2022-08-23 | 2022-08-15 | 2022-08-04 | 0.583551 | Cash | |||
| 2023-03-24 | 2023-04-04 | 2023-03-27 | 2023-02-02 | 1.18874 | Cash | |||
| 2023-08-18 | 2023-08-29 | 2023-08-21 | 2023-08-10 | 0.883561 | Cash | |||
| 2024-03-22 | 2024-04-02 | 2024-03-25 | 2024-01-31 | 0.92985 | Cash |
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2014-01-09 | 2014-01-03 | 2014-01-08 00:00:00 -0500 | 0.2 | 5.0 | 1.0 |